AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9466097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg pre-operatively and ketorolac 20 mg intra-operatively (Group C)
Number of subjects: 137
Study 9466097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg pre-operatively and placebo intra-operatively (Group D)
Number of subjects: 137
Study 7887164 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution 5% applied prior to preoperative wash of the fornices with normal saline.
Number of subjects: 100
Study 7887164 — intervention group
Group type: COMPARATOR
Intervention: Normal saline wash immediately before surgery (Group A).
Number of subjects: 100
Study 2895319 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenprocoumon (60 patients)
Number of subjects: 119
Study 2895319 — intervention group
Group type: COMPARATOR
Intervention: No treatment (59 patients)
Number of subjects: 119
Study 30894441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic‐assisted hematoma evacuation
Number of subjects: 3386
Study 30894441 — intervention group
Group type: COMPARATOR
Intervention: Control arms (various interventions)
Number of subjects: 3386
Study 28298369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (GDM risk factors)
Number of subjects: 289
Study 28298369 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care group (GDM risk factors)
Number of subjects: 289
Study 28298369 — intervention group
Group type: EXPERIMENTAL
Intervention: Early GDM group
Number of subjects: 289
Study 28298369 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (no GDM risk factors)
Number of subjects: 289
Study 28298369 — intervention group
Group type: COMPARATOR
Intervention: Early GDM group compared to healthy control group
Number of subjects: 289
Study 25433970 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine administered by male operators to female subjects
Number of subjects: 200
Study 25433970 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine administered by female operators to male subjects
Number of subjects: 200
Study 25433970 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine administered by male operators to male subjects
Number of subjects: 200
Study 25433970 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine administered by female operators to female subjects
Number of subjects: 200
Study 23607736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 17
Study 23607736 — intervention group
Group type: COMPARATOR
Intervention: Placebo (laser device switched off)
Number of subjects: 17
Study 20110375 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple inflow pulsed arterial spin-labeling (ASL)
Number of subjects: 15
Study 20110375 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 15
Study 18628449 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-arm experimental treatments
Number of subjects: 0
Study 18628449 — intervention group
Group type: COMPARATOR
Intervention: Common control arm
Number of subjects: 0
Study 16009478 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with Asperger's syndrome (AS)
Number of subjects: 0
Study 16009478 — intervention group
Group type: COMPARATOR
Intervention: Neurotypical (NT) controls
Number of subjects: 0
Study 16009478 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with Asperger's syndrome (AS)
Number of subjects: 0
Study 16009478 — intervention group
Group type: COMPARATOR
Intervention: Neurotypical (NT) controls (children)
Number of subjects: 0
Study 12973834 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) - 2 cycles
Number of subjects: 0
Study 12973834 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT) - 1 cycle
Number of subjects: 0
Study 12973834 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 10424376 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous insufficiency diagnosed in men (14.6%) and women (33.6%)
Number of subjects: 3065
Study 10424376 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicose veins diagnosed in men (74.5%) and women (54.2%)
Number of subjects: 3065
Study 10424376 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations found with sex, age, body mass index, and number of pregnancies
Number of subjects: 3065
Study 8710750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride in candy based lozenges
Number of subjects: 6
Study 8710750 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous solutions of the lozenges
Number of subjects: 6
Study 1711614 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (64 mmol/day)
Number of subjects: 84
Study 1711614 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide (10 mg/day)
Number of subjects: 84
Study 6354023 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (18 mg nebulized)
Number of subjects: 8
Study 6354023 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulphate (3 mg nebulized)
Number of subjects: 8
Study 6354023 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulphate (18 mg nebulized)
Number of subjects: 8
Study 6354023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30874369 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic resistance exercise intervention
Number of subjects: 154
Study 30874369 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise control
Number of subjects: 154
Study 27773851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal allergen injections (7 ng of Phl p 5 major allergen)
Number of subjects: 93
Study 27773851 — intervention group
Group type: COMPARATOR
Intervention: Histamine control
Number of subjects: 93
Study 27513252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (5%)
Number of subjects: 24
Study 27513252 — intervention group
Group type: COMPARATOR
Intervention: Propofol (0.75 mg/kg iv)
Number of subjects: 24
Study 24290345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose/inulin 7 g/d
Number of subjects: 22
Study 24290345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 22
Study 22122999 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin only once daily
Number of subjects: 15
Study 22122999 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin + 20 mg famotidine twice daily
Number of subjects: 15
Study 22122999 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole once daily
Number of subjects: 15
Study 22122999 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rabeprazole once daily
Number of subjects: 15
Study 20149706 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EXG, n=25) with self‐controlled exercise for at least 150 min/week and one additional supervised exercise session/week
Number of subjects: 50
Study 20149706 — intervention group
Group type: COMPARATOR
Intervention: Control group (COG, n=25) with no exercise instructions
Number of subjects: 50
Study 17395869 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (balloon angioplasty or stenting)
Number of subjects: 16
Study 17395869 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 16
Study 15802975 — intervention group
Group type: EXPERIMENTAL
Intervention: ddI + TDF
Number of subjects: 570
Study 15802975 — intervention group
Group type: EXPERIMENTAL
Intervention: High ddI doses or taking a third NA
Number of subjects: 570
Study 15802975 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of ddI
Number of subjects: 570
Study 15802975 — intervention group
Group type: COMPARATOR
Intervention: Other NA combinations (including ddI or TDF separately)
Number of subjects: 570
Study 11867504 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC) 2 x 600 mg oral tablets
Number of subjects: 41
Study 11867504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 10464891 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 800 micrograms per day
Number of subjects: 13
Study 10464891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8557242 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogue (B28Asp)
Number of subjects: 14
Study 8557242 — intervention group
Group type: COMPARATOR
Intervention: Actrapid HM
Number of subjects: 14
Study 8557242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (B28Asp) and Actrapid HM
Number of subjects: 14
Study 2183735 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle with direct sonographic guidance
Number of subjects: 52
Study 2183735 — intervention group
Group type: COMPARATOR
Intervention: Needle with catheter
Number of subjects: 52
Study 2183735 — intervention group
Group type: COMPARATOR
Intervention: Needle only
Number of subjects: 52
Study 396846 — intervention group
Group type: EXPERIMENTAL
Intervention: Madecassol
Number of subjects: 0
Study 30973115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tell Your Story (TYS) online stigma reduction intervention
Number of subjects: 103
Study 30973115 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 103
Study 31006728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl icosapentate (EPA) 1.8 g t.i.d.
Number of subjects: 0
Study 31006728 — intervention group
Group type: COMPARATOR
Intervention: EPA+DHA 2 g s.i.d.
Number of subjects: 0
Study 27935767 — intervention group
Group type: EXPERIMENTAL
Intervention: HE+PA
Number of subjects: 436
Study 27935767 — intervention group
Group type: COMPARATOR
Intervention: HE
Number of subjects: 436
Study 27935767 — intervention group
Group type: COMPARATOR
Intervention: PA
Number of subjects: 436
Study 27935767 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 436
Study 26281201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment and azathioprine 2 mg/kg/day
Number of subjects: 20
Study 26281201 — intervention group
Group type: COMPARATOR
Intervention: Control group with azathioprine 2 mg/kg/day, hormone ointment 1 mg/day, and metronidazole suppositories 250 mg/day
Number of subjects: 20
Study 26281201 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDAI scores in the study group
Number of subjects: 20
Study 26281201 — intervention group
Group type: COMPARATOR
Intervention: PCDAI scores in the control group
Number of subjects: 20
Study 23794338 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, amoxicillin, and omeprazole
Number of subjects: 165
Study 23794338 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin, amoxicillin, and omeprazole
Number of subjects: 165
Study 23794338 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, amoxicillin, and omeprazole (subgroup with peptic ulcer disease)
Number of subjects: 165
Study 23794338 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin, amoxicillin, and omeprazole (subgroup with peptic ulcer disease)
Number of subjects: 165
Study 21784839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 21784839 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (100 mg/d losartan)
Number of subjects: 33
Study 21784839 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB plus diuretics (100 mg/d losartan plus 25 mg/d hydrochlorothiazide)
Number of subjects: 33
Study 21784839 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular and low sodium diets (193 ± 62 versus 93 ± 52 mmol Na(+)/d)
Number of subjects: 33
Study 19338552 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde ureteroscopy and holmium:YAG laser lithotripsy
Number of subjects: 164
Study 19338552 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 164
Study 17152394 — intervention group
Group type: EXPERIMENTAL
Intervention: infant‐parent psychotherapy (IPP)
Number of subjects: 137
Study 17152394 — intervention group
Group type: EXPERIMENTAL
Intervention: psychoeducational parenting intervention (PPI)
Number of subjects: 137
Study 17152394 — intervention group
Group type: COMPARATOR
Intervention: community standard (CS)
Number of subjects: 137
Study 17152394 — intervention group
Group type: COMPARATOR
Intervention: nonmaltreating families (NC)
Number of subjects: 137
Study 15103878 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 188
Study 15103878 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management with bleeding at inclusion
Number of subjects: 188
Study 15103878 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management without bleeding but with a non-viable pregnancy
Number of subjects: 188
Study 10954001 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin D,L-lysine (18 mg/kg)
Number of subjects: 12
Study 10954001 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 12
Study 9197046 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooming-in
Number of subjects: 24
Study 9197046 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 8243524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaglobin (IgM-enriched intravenous immunoglobulin)
Number of subjects: 1000
Study 3514727 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 533
Study 3514727 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 533
Study 30095659 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic infusion of phenylephrine
Number of subjects: 60
Study 30095659 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study 27751846 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (160 mg per day, 3 weeks on and 1 week off)
Number of subjects: 182
Study 27751846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 27751846 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 182
Study 24916203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) imaging with septal flash (SF) assessment
Number of subjects: 52
Study 24916203 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of myocardial scar combined with presence of SF
Number of subjects: 52
Study 24916203 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of SF
Number of subjects: 52
Study 22397215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium enoxaparin treatment for 10 days, followed by an additional 10 days after a 10-day no treatment period.
Number of subjects: 60
Study 22397215 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 60
Study 20546462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous plus oral iron (single intravenous iron polymaltose infusion + daily oral ferrous sulphate 250 mg)
Number of subjects: 200
Study 20546462 — intervention group
Group type: COMPARATOR
Intervention: Oral iron only (daily oral ferrous sulphate 250 mg)
Number of subjects: 200
Study 20546462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous plus oral iron
Number of subjects: 200
Study 20546462 — intervention group
Group type: COMPARATOR
Intervention: Oral iron only
Number of subjects: 200
Study 18192624 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school treatment program (10-week duration)
Number of subjects: 23
Study 18192624 — intervention group
Group type: COMPARATOR
Intervention: Community comparison (control group)
Number of subjects: 23
Study 16152836 — intervention group
Group type: EXPERIMENTAL
Intervention: Hailong Juanxiao Recipe combined with Kechuanping sticking on Yongquan acupoint (HKSYA)
Number of subjects: 150
Study 16152836 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (control group)
Number of subjects: 150
Study 16152836 — intervention group
Group type: EXPERIMENTAL
Intervention: HKSYA
Number of subjects: 150
Study 15589088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methadone
Number of subjects: 6
Study 15589088 — intervention group
Group type: COMPARATOR
Intervention: Usual opioid (control)
Number of subjects: 6
Study 11759825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 110
Study 11759825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/day
Number of subjects: 110
Study 11759825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/every other day
Number of subjects: 110
Study 11759825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (all doses)
Number of subjects: 110
Study 11759825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 9149991 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of hyaluronidase and methylprednisolone
Number of subjects: 70
Study 9149991 — intervention group
Group type: COMPARATOR
Intervention: Instillation of methylprednisolone alone
Number of subjects: 70
Study 7956335 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation
Number of subjects: 25
Study 7956335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2962597 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with Gd‐DTPA (MRI+)
Number of subjects: 50
Study 2962597 — intervention group
Group type: COMPARATOR
Intervention: MRI without Gd
Number of subjects: 50
Study 2962597 — intervention group
Group type: COMPARATOR
Intervention: CT with intravenous contrast enhancement
Number of subjects: 50
Study 31707860 — intervention group
Group type: EXPERIMENTAL
Intervention: SNF472 300 mg
Number of subjects: 274
Study 31707860 — intervention group
Group type: EXPERIMENTAL
Intervention: SNF472 600 mg
Number of subjects: 274
Study 31707860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 29174303 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 30
Study 29174303 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study 27836011 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ECT
Number of subjects: 147
Study 27836011 — intervention group
Group type: COMPARATOR
Intervention: Non-ECT
Number of subjects: 147
Study 24824633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg twice a day
Number of subjects: 167
Study 24824633 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 2 mg three times a day
Number of subjects: 167
Study 23328996 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (30 mg/m²) and cisplatin (30 mg/m²) every week for five cycles plus external radiation (46-54 Gy) followed by high-dose rate brachytherapy (12-24 Gy)
Number of subjects: 285
Study 23328996 — intervention group
Group type: COMPARATOR
Intervention: Single-agent cisplatin (40 mg/m²) every week for five cycles plus external radiation (46-54 Gy) followed by high-dose rate brachytherapy (12-24 Gy)
Number of subjects: 285
Study 19956928 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTB grafts fixed with metal interference screws
Number of subjects: 115
Study 19956928 — intervention group
Group type: COMPARATOR
Intervention: DLSG grafts fixed with Bone Mulch Screws and WasherLoc Screws
Number of subjects: 115
Study 19753397 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based instruction (CBI)
Number of subjects: 62
Study 19753397 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based instruction
Number of subjects: 62
Study 16750611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 40
Study 16750611 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 40
Study 12833203 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 30
Study 11072806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 83
Study 11072806 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 83
Study 11072806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium with PORP
Number of subjects: 83
Study 11072806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium without PORP
Number of subjects: 83
Study 8630937 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU infusions plus oral HCFU administration (Group A)
Number of subjects: 269
Study 8630937 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU injections (Group B)
Number of subjects: 269
Study 1558344 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (325 mg aspirin, 75 mg dipyridamole, starting 12 hours preoperatively and continuing for 1 year)
Number of subjects: 163
Study 1558344 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication identical in appearance to the study drugs
Number of subjects: 163
Study 1558344 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 163
Study 1558344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 2859043 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg betaxolol
Number of subjects: 12
Study 2859043 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg propranolol LA
Number of subjects: 12
Study 2859043 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 12
Study 2859043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2859043 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol and Atenolol
Number of subjects: 12
Study 2859043 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12
Study 2859043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer step counts
Number of subjects: 12
Study 29855153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 175
Study 29855153 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (0.7 mg implant)
Number of subjects: 175
Study 26669570 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietary counselling session and group dietary counselling session in addition to standard counselling
Number of subjects: 242
Study 26669570 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal dietary counselling according to the Finnish Nutrition Recommendations
Number of subjects: 242